Search
for
Sort by
Research
240-270 / 1000+ resultsresearch Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib is effective for long-term treatment of severe alopecia areata.
research Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.
research Expression of Langerhans cell antigens in the hair follicles in alopecia areata
research Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA
Disease-specific tools better assess quality of life in alopecia areata patients.
research Beard hair response in Alopecia Areata Universalis treated with baricitinib
Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research Finasteride Tablets
research Finasteride Tablets
research Evaluation of the serum level of regulation upon activation of normal T-cell expressed and secreted protein in different types of alopecia areata
research Randomized Study to Evaluate the Efficacy of Platelet Rich Plasma, Intralesional Triamcinolone Acetonide and Intralesional Normal Saline in Moderate to Severe Alopecia Areata
Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.
research Proceedings of the 7thworld congress of hair research
The conference discussed various hair disorders and treatments, including the use of topical steroids, high doses of cetrizine, and hair grafting, as well as the psychological impact of hair loss.
research Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes
Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.
research The β9 Loop Domain of PA-PLA1α Has a Crucial Role in Autosomal Recessive Woolly Hair/Hypotrichosis
A specific mutation in PA-PLA1α causes abnormal hair growth.
research Clinical Outcomes of Platelet-rich Plasma Injections in the Treatment of Androgenetic Alopecia
research Meetings and Studies: Review of the Joint 3rd Asian & 5th Indian Associations of Hair Restoration Meeting—HAIRCON 2013
Unable to provide a summary as the document content is not provided.
research Classification and Scoring of Androgenetic Alopecia (Male and Female Pattern)
research Comparative study between fractional carbon dioxide laser versus intralesional steroids injection in treatment of alopecia areata
Fractional CO2 laser is more effective and safer than steroid injections for treating alopecia areata.
research Platelet-Rich Plasma (PRP) As A New Approach And Promising Therapy In Patients With Alopecia Areata
PRP is a safe and effective treatment for hair growth in alopecia areata.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Evaluation of fractional carbon dioxide laser alone versus its combination with betamethasone valerate in treatment of alopecia areata, a clinical and dermoscopic study
The fractional carbon dioxide laser is a safe and effective treatment for alopecia areata and works better than betamethasone valerate cream alone.
research Objective and Subjective Assessments of the Response of Photobiomodulation Therapy Against Alopecia Areata
Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
research Alopecia in adolescents-A survey
The document's conclusion cannot be provided because the document is not accessible or understandable.
research Italian Society of Hair Restoration: XII International Congress Milan, Italy • May 31–June 2, 2007
research 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
research Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
research The new regenerative and innovative strategies in hair loss
New treatments for hair loss, including a compound called "ALRV5XR", platelet-rich plasma, and Adult Stem Cell-based therapy, are showing promise, but more trials are needed for confirmation.